Opiate Substitution Treatment

"Opiate Substitution Treatment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Medical treatment for opioid dependence using a substitute opiate such as METHADONE or BUPRENORPHINE.

Descriptor ID	D058850
MeSH Number(s)	E02.319.620
Concept/Terms	Opiate Substitution Treatment Opiate Substitution Treatment Opiate Substitution Treatments Substitution Treatment, Opiate Substitution Treatments, Opiate Treatment, Opiate Substitution Treatments, Opiate Substitution Opioid Substitution Treatment Opioid Substitution Treatments Substitution Treatment, Opioid Substitution Treatments, Opioid Treatment, Opioid Substitution Treatments, Opioid Substitution Opioid Substitution Therapy Opioid Substitution Therapies Substitution Therapies, Opioid Substitution Therapy, Opioid Therapies, Opioid Substitution Therapy, Opioid Substitution Opiate Replacement Therapy Opiate Replacement Therapies Replacement Therapies, Opiate Replacement Therapy, Opiate Therapies, Opiate Replacement Therapy, Opiate Replacement Opioid Replacement Therapy Opioid Replacement Therapies Replacement Therapies, Opioid Replacement Therapy, Opioid Therapies, Opioid Replacement Therapy, Opioid Replacement

Below are MeSH descriptors whose meaning is more general than "Opiate Substitution Treatment".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Drug Therapy [E02.319]
Opiate Substitution Treatment [E02.319.620]

Below are MeSH descriptors whose meaning is more specific than "Opiate Substitution Treatment".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Opiate Substitution Treatment" by people in this website by year, and whether "Opiate Substitution Treatment" was a major or minor topic of these publications.

Bar chart showing 132 publications over 15 distinct years, with a maximum of 19 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2010	1	0	1
2011	2	0	2
2012	6	1	7
2013	3	1	4
2014	5	0	5
2015	9	0	9
2016	6	2	8
2017	6	3	9
2018	7	2	9
2019	5	6	11
2020	4	5	9
2021	1	10	11
2022	0	19	19
2023	0	10	10
2024	11	7	18

Below are the most recent publications written about "Opiate Substitution Treatment" by people in Profiles.

Kang AW, Bailey A, Surace A, Stein L, Rohsenow D, Martin RA. Medications for opioid use disorders among incarcerated persons and those in the community supervision setting: exploration of implementation issues with key stakeholders. Addict Sci Clin Pract. 2024 Dec 18; 19(1):95.

View in: PubMed
Pivovarova E, Planas Garcia BY, Friedmann PD, Stopka TJ, Santelices C, Evans EA. Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers. J Addict Med. 2025 Jan-Feb 01; 19(1):95-101.

View in: PubMed
Andraka-Christou B, Viglione J, Ahmed F, Del Pozo B, Atkins DN, Clark MH, Totaram R, Pivovarova E. Factors affecting problem-solving court team decisions about medications for opioid use disorder. J Subst Use Addict Treat. 2025 Jan; 168:209525.

View in: PubMed
Chatterjee A, Stewart EA, Assoumou SA, Chrysanthopoulou SA, Zwick H, Harris RA, O'Dea R, Schackman BR, White LF, Linas BP. Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in Massachusetts. JAMA Netw Open. 2024 Oct 01; 7(10):e2437233.

View in: PubMed
Stopka TJ, Rottapel R, Friedmann PD, Pivovarova E, Evans EA. Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study. Addict Sci Clin Pract. 2024 Sep 12; 19(1):68.

View in: PubMed
Chan B, Cook R, Levander X, Wiest K, Hoffman K, Pertl K, Petluri R, McCarty D, Korthuis PT, Martin SA. Buprenorphine discontinuation in telehealth-only treatment for opioid use disorder: A longitudinal cohort analysis. J Subst Use Addict Treat. 2024 Dec; 167:209511.

View in: PubMed
Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA. Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2024 Sep 03; 7(9):e2434704.

View in: PubMed
Grande LA, Hutch T, Jack K, Mironov W, Iwuoha J, Muy-Rivera M, Grillo J, Martin SA, Herring A. Ketamine-assisted buprenorphine initiation: a pilot case series. Addict Sci Clin Pract. 2024 Aug 29; 19(1):60.

View in: PubMed
Helm A, Shaffer P, Gonzalez G, Li W, Olmstead T, Berlowitz D, Epstein E, Smelson D. Protocol of a randomized controlled trial examining psychosocial enhancement and standard medication treatment for co-occurring opioid use and mental health disorders: A half fractional factorial randomized controlled trial. Contemp Clin Trials. 2024 Oct; 145:107668.

View in: PubMed
Williams AR, Mauro CM, Chiodo L, Huber B, Cruz A, Crystal S, Samples H, Nowels M, Wilson A, Friedmann PD, Remien RH, Olfson M. Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care. Drug Alcohol Depend. 2024 Oct 01; 263:112389.

View in: PubMed

People

Explore

Similar Concepts

Top Journals